NIVOLUMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 4,197 adverse event reports in the FDA FAERS database where NIVOLUMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for NIVOLUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 11,216 | 12.8% | 11,211 | 780 |
| Malignant neoplasm progression | 9,363 | 10.7% | 5,146 | 4,330 |
| Off label use | 5,208 | 5.9% | 1,240 | 1,725 |
| Diarrhoea | 4,692 | 5.4% | 623 | 2,506 |
| Fatigue | 3,709 | 4.2% | 409 | 1,425 |
| Pyrexia | 3,454 | 3.9% | 532 | 2,501 |
| Intentional product use issue | 3,297 | 3.8% | 1,461 | 827 |
| Rash | 2,816 | 3.2% | 297 | 1,131 |
| Nausea | 2,805 | 3.2% | 378 | 1,495 |
| Decreased appetite | 2,619 | 3.0% | 452 | 1,429 |
| Dyspnoea | 2,527 | 2.9% | 596 | 1,575 |
| Pneumonia | 2,281 | 2.6% | 792 | 1,676 |
| Colitis | 2,123 | 2.4% | 333 | 1,306 |
| Pneumonitis | 2,076 | 2.4% | 564 | 1,130 |
| Hypothyroidism | 1,939 | 2.2% | 267 | 946 |
Other Indications for NIVOLUMAB
Product used for unknown indication (12,733)
Malignant melanoma (10,599)
Non-small cell lung cancer (9,987)
Renal cell carcinoma (6,514)
Metastatic malignant melanoma (4,628)
Metastatic renal cell carcinoma (3,857)
Gastric cancer (3,856)
Non-small cell lung cancer recurrent (2,703)
Renal cancer (1,756)
Oesophageal carcinoma (1,555)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)
ATEZOLIZUMAB (1,262)